Pulmonary Inflammatory Response in Lethal COVID-19 Reveals Potential Therapeutic Targets and Drugs in Phases III/IV Clinical Trials

• Main Authors: Andrés López-Cortés (Author), Santiago Guerrero (Author), Esteban Ortiz-Prado (Author), Verónica Yumiceba (Author), Antonella Vera-Guapi (Author), Ángela León Cáceres (Author), Katherine Simbaña-Rivera (Author), Ana María Gómez-Jaramillo (Author), Gabriela Echeverría-Garcés (Author), Jennyfer M. García-Cárdenas (Author), Patricia Guevara-Ramírez (Author), Alejandro Cabrera-Andrade (Author), Lourdes Puig San Andrés (Author), Doménica Cevallos-Robalino (Author), Jhommara Bautista (Author), Isaac Armendáriz-Castillo (Author), Andy Pérez-Villa (Author), Andrea Abad-Sojos (Author), María José Ramos-Medina (Author), Ariana León-Sosa (Author), Estefanía Abarca (Author), Álvaro A. Pérez-Meza (Author), Karol Nieto-Jaramillo (Author), Andrea V. Jácome (Author), Andrea Morillo (Author), Fernanda Arias-Erazo (Author), Luis Fuenmayor-González (Author), Luis Abel Quiñones (Author), Nikolaos C. Kyriakidis (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: It is imperative to identify drugs that allow treating symptoms of severe COVID-19. Respiratory failure is the main cause of death in severe COVID-19 patients, and the host inflammatory response at the lungs remains poorly understood.Methods: Therefore, we retrieved data from post-mortem...